Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RaniPill capsule containing octreotide
RaniPill containing octreotide · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RaniPill capsule containing octreotide | COMBINATION_PRODUCT | Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule. |
The RaniPill containing octreotide is an investigational oral drug delivery product from Rani Therapeutics Holdings, Inc. It combines the RaniPill capsule platform with octreotide, a small molecule, to deliver the drug by mouth rather than by injection. It is in Phase 1 clinical development.
Rani Therapeutics Holdings, Inc., which trades under the ticker RANI, is the developer of the RaniPill containing octreotide. The company is also the sponsor of the first-in-human study of the RaniPill oral drug delivery platform.
The RaniPill containing octreotide is in Phase 1 development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
The RaniPill containing octreotide has been studied in NCT03798912, titled A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform. That Phase 1 trial is completed and enrolled 62 participants. It was an uncontrolled study conducted in healthy volunteers.
Yes. The RaniPill containing octreotide is also known as the RaniPill capsule containing octreotide. Both names refer to the same investigational product from Rani Therapeutics Holdings, Inc. that pairs the RaniPill oral delivery platform with octreotide.